A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Naloxegol (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2019 Planned End Date changed from 1 Oct 2020 to 1 Aug 2027.
- 01 Apr 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Aug 2027.
- 31 Aug 2018 Biomarkers information updated